ASCO 2013 - Poster: Outcomes in patients with liver or lung metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial

CHICAGO, IL USA ( - Presented by Yohann Loriot,1 Karim Fizazi,1 Johann Sebastian De Bono,2 David Forer,3 Mohammad Hirmand,3 Howard I. Scher4 at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA

asco 2013 loriot poster thumb

1Institut Gustave Roussy, University of Paris Sud, Villejuif, France; 2The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; 3Medivation, Inc., San Francisco, CA; 4Memorial Sloan-Kettering Cancer Center, New York, NY

The ASCO Annual Meeting brings together more than 25,000 oncology professionals from a broad range of specialties, making it an excellent venue for exploring the theme of the Meeting — "Building Bridges to Conquer Cancer."

asco x

View Full ASCO 2013 Coverage